Advertisement

Цитозар

Основна информация

  • Търговско наименование:
  • Цитозар (Cytosar)
  • Предлага се от:
  • Pharmacia Italia S.p.A.
  • дозиране:
  • 100 mg x 1
  • Лекарствена форма:
  • прах и разтворител за инжекционен разтвор
  • Композиция:
  • прах и разтворител за инжекционен разтвор 100 mg x 1
  • Използвай за:
  • Хората
  • Вид на лекарството:
  • алопатични наркотици
Advertisement

Документи

Локализация

  • Предлага се в:
  • Цитозар (Cytosar)
    България
  • Език:
  • български

Друга информация

Състояние

  • Източник:
  • Изпълнителна агенция по лекарствата - Bulgarian Drug Agency - Bulgaria
  • Последна актуализация:
  • 09-08-2016

Листовка за пациента


3-8-2017

FDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia

FDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia

The U.S. Food and Drug Administration today approved Vyxeos for the treatment of adults with two types of acute myeloid leukemia (AML): newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of chemotherapy drugs daunorubicin and cytarabine.

FDA - U.S. Food and Drug Administration

21-11-2017

CYTARABINE Injection, Solution [Hospira, Inc.]

CYTARABINE Injection, Solution [Hospira, Inc.]

Updated Date: Nov 21, 2017 EST

US - DailyMed

12-6-2017

DEPOCYT (Cytarabine) Injection, Lipid Complex [Sigma-Tau Pharmaceuticals, Inc.]

DEPOCYT (Cytarabine) Injection, Lipid Complex [Sigma-Tau Pharmaceuticals, Inc.]

Updated Date: Jun 12, 2017 EST

US - DailyMed

21-12-2016

EU/3/11/942 (Jazz Pharmaceuticals Ireland Ltd)

EU/3/11/942 (Jazz Pharmaceuticals Ireland Ltd)

EU/3/11/942 (Active substance: Liposomal combination of cytarabine and daunorubicin) - Transfer of orphan designation - Commission Decision (2016)8908 of Wed, 21 Dec 2016 European Medicines Agency (EMA) procedure number: EMA/OD/070/11/T/01

Europe -DG Health and Food Safety

Advertisement